Oculis (OCS)
Develops investigational therapies for neuro-ophthalmology and dry eye disease.
$10.14
vs last close−0.57 (−5.32%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≥ 38.64% | 23.22M ADS | |
|---|---|---|---|
| 62 holders · as of Jun 30, 2026 | |||
| Other | ≤ 61.36% | 36.87M ADS | |
| remainder | |||
60.09M ADS as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Institutional filings for OCSAW (4% of the company) are not on file here, so the institutional figure is a floor.
This company has 2 share classes; every stake here is a share of the whole company.
13F, as of Jun 30, 2026
62 holders · 23.22M shares · 21 new positions · 43 increased · 10 reduced · 19 closed
| Holder | Shares | % of company | Chg q/q | Filed |
|---|---|---|---|---|
| Eqt Fund Management S.A R.L. | 6.95M | 11.57% | +1.05M | Aug 13, 2026 |
| Abrdn PLC | 2.16M | 3.59% | +412.9K | Jul 31, 2026 |
| Millennium Management LLC | 2.04M | 3.40% | +1.13M | Aug 14, 2026 |
| Pivotal Bioventure Partners Investment Advisor LLC | 1.51M | 2.51% | −174.0K | Aug 13, 2026 |
| Citadel Advisors LLC | 987.2K | 1.64% | +825.9K | Sep 2, 2026 |
| Braidwell LP | 834.2K | 1.39% | +834.2Knew | Aug 14, 2026 |
| Perceptive Advisors LLC | 808.8K | 1.35% | +315.0K | Aug 14, 2026 |
| Saturn V Capital Management LLC | 684.9K | 1.14% | +168.1K | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| LSP 7 Cooperatieve U.A. | 11.80% | 6.95M | 13G | Apr 29, 2026 |
Form 4
Latest trades
Nothing filed in the last 12 months.
House and Senate disclosures
Not reported.